Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Straus and colleagues1 stated that "the Antiplatelet Trialists' Collaboration
[ATC]2 did not find that adding dipyridamole
to aspirin resulted in significant benefit over the use of aspirin alone,
but they noted that a single randomized trial found that the addition of extended-release
dipyridamole to aspirin decreased the risk of death significantly." The ATC
authors claimed that the results of this "single randomized trial" (ESPS-2),3 which demonstrated significant reduction in stroke
risk, was inconsistent with preceding negative trials of dipyridamole plus
aspirin for cardiovascular disease prevention and that its results may have
arisen "largely or wholly by the play of chance."2
Gebel JM, Caplan LR. Reducing the Risk of Stroke. JAMA. 2003;289(15):1927–1929. doi:10.1001/jama.289.15.1927
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: